ImmunoGen, Inc. Announces Conference Call to Discuss its Fourth Quarter and Fiscal Year 2015 Financial Results
July 15 2015 - 8:00AM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a
biotechnology company that develops novel anticancer therapeutics
using its antibody-drug conjugate (ADC) technology, today announced
that the Company will host a conference call at 8:00 a.m. ET on
Friday, July 31, 2015, to discuss ImmunoGen's financial results for
the three-month period and fiscal year ended June 30, 2015 and its
guidance for its 2016 fiscal year. Management also will provide an
update on the Company.
To access the live call by phone, dial 913-312-0951; the
conference ID is 2265897. The call also may be accessed through the
Investors section of the Company's website, www.immunogen.com.
Following the live webcast, a replay of the call will be available
at the same location through August 14, 2015.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The
Company’s ADC technology uses tumor-targeting antibodies to deliver
an ImmunoGen cell-killing agent specifically to cancer cells. The
Company utilizes its ADC technology with its antibodies to create
ImmunoGen product candidates and also out-licenses limited rights
to use its technology to other companies. Roche’s Kadcyla® is the
first marketed product with ImmunoGen’s ADC technology. More
information about the Company can be found at
www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member
of the Roche Group.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150715005083/en/
For Investors:ImmunoGen, Inc.Carol Hausner,
781-895-0600info@immunogen.comorFor Media:Pure Communications,
Inc.Dan Budwick, 973-271-6085
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Apr 2023 to Apr 2024